Added to YB: 2025-04-30
Pitch date: 2025-03-11
STOK [bullish]
Stoke Therapeutics, Inc.
+259.64%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression.
Market Cap
$1.9B
Pitch Price
$8.25
Price Target
N/A
Dividend
N/A
EV/EBITDA
N/A
P/E
-10.68
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Show full summary:
Stoke Therapeutics, Inc. - $STOK
STOK: Zorevunersen for Dravet Syndrome at discount due to catalyst desert (no Ph3 data until 2027). High PoS asset showing >50% seizure reduction at 70mg dose, potential cognitive benefits. Biogen deal provides $165M upfront + 30% Ph3 costs. $500M market cap vs potential $1B+ peak sales. 3x revenue valuation with PRV upside.
Read full article (6 min)